Remove In-Vitro Remove Life Science Remove Protein Remove Reagent
article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

As life science operates globally, the vision for the business was always to bring aptamers as an antibody alternative to researchers worldwide. What advice would you offer to similar start-ups?    AT: Integral to Aptamer Group’s offering is an in-depth understanding of molecular science.

article thumbnail

Reflecting on ELRIG’s Drug Discovery 2022 

Drug Discovery World

The DDW team spent 4-5 October, 2022 at ELRIG’s annual meeting, Drug Discovery 2022, which remains Europe’s largest meeting for life sciences industry professionals and took place at ExCel, London, UK. Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery.

Drugs 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Receptor Occupancy Assays by Flow Cytometry: Benefits for Clinical Trials

XTalks

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. What is Flow Cytometry?

article thumbnail

Highlights from SLAS2023: Day One

Drug Discovery World

“We’re transforming drug discovery, and it all begins in the lab where researchers can leverage multimode plate reader technology like the EnVision Nexus system to increase R&D productivity at nearly every stage of their process,” said PerkinElmer Senior Vice President of Life Sciences Alan Fletcher. “By

Drugs 52
article thumbnail

Transforming high-throughput screening with mass spectrometry

Drug Discovery World

Reducing assay volumes from about 200 µL to 1 µL ha s cut the quantities of reagents and consumables needed, while automation has replaced manual handling, so lowering running and personnel costs. . The rapid evolution of HTS to meet industry demand . Overcoming challenges in HTS using mass spectrometry .

Drugs 52